A detailed history of Axa S.A. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Axa S.A. holds 232,266 shares of RCUS stock, worth $3.65 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
232,266
Previous 232,200 0.03%
Holding current value
$3.65 Million
Previous $3.54 Million 0.42%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $903 - $1,188
66 Added 0.03%
232,266 $3.55 Million
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $1,867 - $2,365
128 Added 0.06%
232,200 $3.54 Million
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $934 - $1,271
63 Added 0.03%
232,072 $4.38 Million
Q4 2023

Jul 16, 2024

SELL
$13.43 - $19.63 $846 - $1,236
-63 Reduced 0.03%
232,009 $4.43 Million
Q4 2023

Feb 14, 2024

SELL
$13.43 - $19.63 $75,342 - $110,124
-5,610 Reduced 2.36%
232,009 $4.43 Million
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $1.58 Million - $2.11 Million
89,450 Added 60.37%
237,619 $4.27 Million
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $34,584 - $44,897
2,038 Added 1.39%
148,169 $3.01 Million
Q1 2023

May 15, 2023

SELL
$15.96 - $23.15 $5,107 - $7,408
-320 Reduced 0.22%
146,131 $2.67 Million
Q4 2022

Feb 14, 2023

SELL
$19.7 - $35.71 $17,434 - $31,603
-885 Reduced 0.6%
146,451 $3.03 Million
Q3 2022

Feb 14, 2023

SELL
$23.23 - $30.07 $1.02 Million - $1.33 Million
-44,074 Reduced 23.03%
147,336 $3.85 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $1.02 Million - $1.33 Million
-44,074 Reduced 23.03%
147,336 $3.85 Million
Q2 2022

Feb 14, 2023

BUY
$17.23 - $37.73 $980,300 - $2.15 Million
56,895 Added 42.3%
191,410 $4.85 Million
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $980,300 - $2.15 Million
56,895 Added 42.3%
191,410 $4.85 Million
Q1 2022

Feb 14, 2023

SELL
$28.92 - $41.83 $370,783 - $536,302
-12,821 Reduced 8.7%
134,515 $4.25 Million
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $4.22 Million - $6.52 Million
134,515 New
134,515 $5.44 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.13B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.